11,067 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Financial Harvest LLC

Financial Harvest LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,067 shares of the medical device company's stock, valued at approximately $756,000. DexCom makes up about 0.5% of Financial Harvest LLC's holdings, making the stock its 19th biggest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC raised its holdings in DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after acquiring an additional 2,879,489 shares during the period. Geode Capital Management LLC increased its holdings in DexCom by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after buying an additional 56,094 shares during the period. Norges Bank bought a new position in DexCom in the 4th quarter valued at about $385,367,000. Northern Trust Corp increased its stake in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after acquiring an additional 753,857 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in DexCom by 171.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after acquiring an additional 2,015,971 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on DXCM shares. Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. The Goldman Sachs Group started coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a research report on Friday. Barclays increased their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Citigroup reissued a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $99.60.

Insider Transactions at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,190 shares of company stock worth $2,281,732 in the last three months. Corporate insiders own 0.32% of the company's stock.

DexCom Stock Performance

DexCom stock traded down $0.21 during midday trading on Friday, reaching $83.89. The stock had a trading volume of 2,616,540 shares, compared to its average volume of 4,442,293. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $113.28. The firm's 50-day moving average price is $84.49 and its 200 day moving average price is $80.19. The firm has a market capitalization of $32.89 billion, a PE ratio of 62.60, a P/E/G ratio of 1.79 and a beta of 1.44. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.